
Shall the billboards of prescription only medicines be hidden at promotional booth? Can banners be placed without opening own booth? If so, which requirements shall be met?
AZS Partners' current summary seeks to have a better understanding of this topic, based on the recently published ruling of the competent authority still known during the inspection as OGYEI (as of 1 August, NNGYK).

The new Hungarian Whistleblower Protection Act, enacted as Act XXV of 2023, marks a significant shift in the country's approach to whistleblowing. This legislation was introduced to align Hungary with the EU/2019/1937 Directive, which mandates whistleblower protection in most EU member states. The primary objective of this law is to enhance transparency, protect employees, and reduce potential harm caused by illegal activities within organizations.

As of 1 August 2023 the National Institute of Pharmacy and Nutrition (abbreviated in Hungarian: ‘OGYÉI’) will cease to exist after more than its 60 years of existence as independent authority and will merge into the National Public Health Centre.
This latter will act as legal successor of OGYÉI under a new name of National Public Health and Pharmacy Centre (abbreviated in Hungarian: ‘NNGYK’).

In force from 1st June 2023: Following several amendments and clarifications to the Government De- cree No. 197/2022 (VI.4.) on Extra Profit Taxes (the “Decree on extraprofit taxes”) which entered into force in December 2022, in the Official Gazette no. 79/ 2023 published on 31 May 2023, the Government decided on new significant changes affecting certain subjects of the pharmaceutical in- dustry regulated by Government Decree no. 206/ 2023 ( V.31) (“Amending Decree no. 4.”) which entered into force as of 1 June 2023.
More Articles …
- New Hungarian whistle-blower laws takes effect!
- New amendment to the government decree on extra profit taxes affecting pharmaceutical manufacturers
- New due diligence obligations under the German Supply Chain Act (“LkSG”)
- Amendment to Government Decree No. 197/2022 (VI.4.) on Extra Profit Taxes affecting pharmaceutical manufacturers